Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1 − CD8 + Tumor-Infiltrating T Cells

Immunity

Volumn 50, Issue 1, 2019, Pages 181-194.e6

  Kurtulus, Sema ^a   Madi, Asaf ^a,b   Escobar, Giulia ^a   Klapholz, Max ^a   Nyman, Jackson ^c   Christian, Elena ^c   Pawlak, Mathias ^a   Dionne, Danielle ^c   Xia, Junrong ^a   Rozenblatt Rosen, Orit ^c   Kuchroo, Vijay K ^a   Regev, Aviv ^c,d,e   Anderson, Ana C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

cancer; CD8 + T cell; checkpoint blockade; dysfunction; exhaustion; immunotherapy; memory; PD 1; single cell; Tim 3

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHECKPOINT KINASE INHIBITOR; CHEMOKINE RECEPTOR CX3CR1; CRE RECOMBINASE; CXCL9 CHEMOKINE; FAS LIGAND; GAMMA INTERFERON; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; KLRG1 PROTEIN; L SELECTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN; TILSOTOLIMOD; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR 7 LIKE 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; HAVCR2 PROTEIN, HUMAN; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HNF1A PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; TRANSCRIPTOME; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL PROLIFERATION; DRUG EFFECT; EXPERIMENTAL MELANOMA; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTE SUBSETS; TRANSCRIPTOME;

EID: 85059794223     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2018.11.014     Document Type: Article

References (75)

1. Agarwal, P., Raghavan, A., Nandiwada, S.L., Curtsinger, J.M., Bohjanen, P.R., Mueller, D.L., Mescher, M.F., Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J. Immunol. 183 (2009), 1695–1704.
2. Ahn, E., Youngblood, B., Lee, J., Lee, J., Sarkar, S., Ahmed, R., Demethylation of the PD-1 promoter is imprinted during the effector phase of CD8 T cell exhaustion. J. Virol. 90 (2016), 8934–8946.
3. Anders, S., Huber, W., Differential expression analysis for sequence count data. Genome Biol., 11, 2010, R106.
4. + T cells in metastases from melanoma patients. J. Clin. Invest. 121 (2011), 2350–2360.
5. Blondel, V.D., Guillaume, J., Lambiotte, R., Lefebvre, E., Fast unfolding of communities in large networks. J. Stat. Mech., 2008, 2008, P10008.
6. Böttcher, J.P., Beyer, M., Meissner, F., Abdullah, Z., Sander, J., Höchst, B., Eickhoff, S., Rieckmann, J.C., Russo, C., Bauer, T., et al. Functional classification of memory CD8(+) T cells by CX3CR1 expression. Nat. Commun., 6, 2015, 8306.
7. + T cells infiltrating human tumors. J. Exp. Med. 215 (2018), 2520–2535.
8. da Silva, I.P., Gallois, A., Jimenez-Baranda, S., Khan, S., Anderson, A.C., Kuchroo, V.K., Osman, I., Bhardwaj, N., Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol. Res. 2 (2014), 410–422.
9. Das, R., Verma, R., Sznol, M., Boddupalli, C.S., Gettinger, S.N., Kluger, H., Callahan, M., Wolchok, J.D., Halaban, R., Dhodapkar, M.V., Dhodapkar, K.M., Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J. Immunol. 194 (2015), 950–959.
10. + dendritic cell function and response to chemotherapy in breast cancer. Cancer Cell 33 (2018), 60–74.e6.
11. Duraiswamy, J., Kaluza, K.M., Freeman, G.J., Coukos, G., Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 73 (2013), 3591–3603.
12. Ellmeier, W., Sunshine, M.J., Losos, K., Hatam, F., Littman, D.R., An enhancer that directs lineage-specific expression of CD8 in positively selected thymocytes and mature T cells. Immunity 7 (1997), 537–547.
13. Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I.F., Sander, C., Kirkwood, J.M., Kuchroo, V., Zarour, H.M., Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 207 (2010), 2175–2186.
14. Fraietta, J.A., Lacey, S.F., Orlando, E.J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A.C., Wang, Y., O'Connor, R.S., Hwang, W.T., et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24 (2018), 563–571.
15. Ganesan, A.P., Clarke, J., Wood, O., Garrido-Martin, E.M., Chee, S.J., Mellows, T., Samaniego-Castruita, D., Singh, D., Seumois, G., Alzetani, A., et al. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat. Immunol. 18 (2017), 940–950.
16. Gerlach, C., Moseman, E.A., Loughhead, S.M., Alvarez, D., Zwijnenburg, A.J., Waanders, L., Garg, R., de la Torre, J.C., von Andrian, U.H., The chemokine receptor CX3CR1 defines three antigen-experienced CD8 T cell subsets with distinct roles in immune surveillance and homeostasis. Immunity 45 (2016), 1270–1284.
17. Ghoneim, H.E., Fan, Y., Moustaki, A., Abdelsamed, H.A., Dash, P., Dogra, P., Carter, R., Awad, W., Neale, G., Thomas, P.G., Youngblood, B., De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell 170 (2017), 142–157.e19.
18. Gilfillan, S., Chan, C.J., Cella, M., Haynes, N.M., Rapaport, A.S., Boles, K.S., Andrews, D.M., Smyth, M.J., Colonna, M., DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J. Exp. Med. 205 (2008), 2965–2973.
19. Gordon, S.R., Maute, R.L., Dulken, B.W., Hutter, G., George, B.M., McCracken, M.N., Gupta, R., Tsai, J.M., Sinha, R., Corey, D., et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545 (2017), 495–499.
20. Gubin, M.M., Zhang, X., Schuster, H., Caron, E., Ward, J.P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C.D., Krebber, W.J., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515 (2014), 577–581.
21. Haymaker, C.L., Wu, R.C., Ritthipichai, K., Bernatchez, C., Forget, M.A., Chen, J.Q., Liu, H., Wang, E., Marincola, F., Hwu, P., Radvanyi, L.G., BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties. OncoImmunology, 4, 2015, e1014246.
22. Hervas-Stubbs, S., Riezu-Boj, J.I., Gonzalez, I., Mancheño, U., Dubrot, J., Azpilicueta, A., Gabari, I., Palazon, A., Aranguren, A., Ruiz, J., et al. Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8(+) T cells. Eur. J. Immunol. 40 (2010), 3389–3402.
23. Hirahara, K., Onodera, A., Villarino, A.V., Bonelli, M., Sciumè G., Laurence, A., Sun, H.W., Brooks, S.R., Vahedi, G., Shih, H.Y., et al. Asymmetric action of STAT transcription factors drives transcriptional outputs and cytokine specificity. Immunity 42 (2015), 877–889.
24. Huang, A.C., Postow, M.A., Orlowski, R.J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J.R., Wenz, B., et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545 (2017), 60–65.
25. Im, S.J., Hashimoto, M., Gerner, M.Y., Lee, J., Kissick, H.T., Burger, M.C., Shan, Q., Hale, J.S., Lee, J., Nasti, T.H., et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537 (2016), 417–421.
26. Iwata, S., Mikami, Y., Sun, H.W., Brooks, S.R., Jankovic, D., Hirahara, K., Onodera, A., Shih, H.Y., Kawabe, T., Jiang, K., et al. The transcription factor T-bet limits amplification of type I IFN transcriptome and circuitry in T helper 1 cells. Immunity 46 (2017), 983–991.e4.
27. Jeannet, G., Boudousquié C., Gardiol, N., Kang, J., Huelsken, J., Held, W., Essential role of the Wnt pathway effector Tcf-1 for the establishment of functional CD8 T cell memory. Proc. Natl. Acad. Sci. USA 107 (2010), 9777–9782.
28. Jiang, X., Zhou, T., Xiao, Y., Yu, J., Dou, S., Chen, G., Wang, R., Xiao, H., Hou, C., Wang, W., et al. Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis. OncoImmunology, 5, 2016, e1211219.
29. Joshi, N.S., Cui, W., Chandele, A., Lee, H.K., Urso, D.R., Hagman, J., Gapin, L., Kaech, S.M., Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 27 (2007), 281–295.
30. Kaech, S.M., Hemby, S., Kersh, E., Ahmed, R., Molecular and functional profiling of memory CD8 T cell differentiation. Cell 111 (2002), 837–851.
31. Kalia, V., Sarkar, S., Subramaniam, S., Haining, W.N., Smith, K.A., Ahmed, R., Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity 32 (2010), 91–103.
32. Kamphorst, A.O., Pillai, R.N., Yang, S., Nasti, T.H., Akondy, R.S., Wieland, A., Sica, G.L., Yu, K., Koenig, L., Patel, N.T., et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc. Natl. Acad. Sci. USA 114 (2017), 4993–4998.
33. Kolde, R., Vilo, J., GOsummaries: an R package for visual functional annotation of experimental data. F1000Res., 4, 2015, 574.
34. Krempski, J., Karyampudi, L., Behrens, M.D., Erskine, C.L., Hartmann, L., Dong, H., Goode, E.L., Kalli, K.R., Knutson, K.L., Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J. Immunol. 186 (2011), 6905–6913.
35. Langmead, B., Trapnell, C., Pop, M., Salzberg, S.L., Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol., 10, 2009, R25.
36. Lefrançois, L., Development, trafficking, and function of memory T-cell subsets. Immunol. Rev. 211 (2006), 93–103.
37. Leong, Y.A., Chen, Y., Ong, H.S., Wu, D., Man, K., Deleage, C., Minnich, M., Meckiff, B.J., Wei, Y., Hou, Z., et al. CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles. Nat. Immunol. 17 (2016), 1187–1196.
38. Levine, J.H., Simonds, E.F., Bendall, S.C., Davis, K.L., Amir, A.D., Tadmor, M.D., Litvin, O., Fienberg, H.G., Jager, A., Zunder, E.R., et al. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell 162 (2015), 184–197.
39. Li, B., Dewey, C.N., RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics, 12, 2011, 323.
40. Li, Y., Liu, S., Hernandez, J., Vence, L., Hwu, P., Radvanyi, L., MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J. Immunol. 184 (2010), 452–465.
41. + T cell function and antitumor immunity. OncoImmunology, 5, 2015, e1085146.
42. Love, M.I., Huber, W., Anders, S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 15, 2014, 550.
43. Luckey, C.J., Bhattacharya, D., Goldrath, A.W., Weissman, I.L., Benoist, C., Mathis, D., Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 103 (2006), 3304–3309.
44. Maaten, L.H.G., Visualizing data using t-SNE. J. Mach. Learn. Res. 9 (2008), 2579–2605.
45. Maaten, L., Learning a Parametric Embedding by Preserving Local Structure. David van, D., Max, W., (eds.) Proceedings of the Twelth International Conference on Artificial Intelligence and Statistics, 2009, Proceedings of Machine Learning Research, PMLR, 384–391.
46. Maekawa, Y., Minato, Y., Ishifune, C., Kurihara, T., Kitamura, A., Kojima, H., Yagita, H., Sakata-Yanagimoto, M., Saito, T., Taniuchi, I., et al. Notch2 integrates signaling by the transcription factors RBP-J and CREB1 to promote T cell cytotoxicity. Nat. Immunol. 9 (2008), 1140–1147.
47. Makowska, Z., Blumer, T., Duong, F.H., La Monica, N., Kandimalla, E.R., Heim, M.H., Sequential induction of type I and II interferons mediates a long-lasting gene induction in the liver in response to a novel toll-like receptor 9 agonist. J. Hepatol. 58 (2013), 743–749.
48. Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34 (2003), 267–273.
49. Ngiow, S.F., von Scheidt, B., Akiba, H., Yagita, H., Teng, M.W., Smyth, M.J., Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res. 71 (2011), 3540–3551.
50. Nishino, M., Ramaiya, N.H., Chambers, E.S., Adeni, A.E., Hatabu, H., Jänne, P.A., Hodi, F.S., Awad, M.M., Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J. Immunother. Cancer, 4, 2016, 84.
51. Pauken, K.E., Sammons, M.A., Odorizzi, P.M., Manne, S., Godec, J., Khan, O., Drake, A.M., Chen, Z., Sen, D.R., Kurachi, M., et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354 (2016), 1160–1165.
52. Philip, M., Fairchild, L., Sun, L., Horste, E.L., Camara, S., Shakiba, M., Scott, A.C., Viale, A., Lauer, P., Merghoub, T., et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 545 (2017), 452–456.
53. Phipson, B., Lee, S., Majewski, I.J., Alexander, W.S., Smyth, G.K., Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression. Ann. Appl. Stat. 10 (2016), 946–963.
54. Picelli, S., Björklund, A.K., Faridani, O.R., Sagasser, S., Winberg, G., Sandberg, R., Smart-seq2 for sensitive full-length transcriptome profiling in single cells. Nat. Methods 10 (2013), 1096–1098.
55. Rangachari, M., Zhu, C., Sakuishi, K., Xiao, S., Karman, J., Chen, A., Angin, M., Wakeham, A., Greenfield, E.A., Sobel, R.A., et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion. Nat. Med. 18 (2012), 1394–1400.
56. Sakuishi, K., Apetoh, L., Sullivan, J.M., Blazar, B.R., Kuchroo, V.K., Anderson, A.C., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207 (2010), 2187–2194.
57. + regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. OncoImmunology, 2, 2013, e23849.
58. Sarkar, S., Kalia, V., Haining, W.N., Konieczny, B.T., Subramaniam, S., Ahmed, R., Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates. J. Exp. Med. 205 (2008), 625–640.
59. + T cells responding to viral infection. Immunity 45 (2016), 1327–1340.
60. Sen, D.R., Kaminski, J., Barnitz, R.A., Kurachi, M., Gerdemann, U., Yates, K.B., Tsao, H.W., Godec, J., LaFleur, M.W., Brown, F.D., et al. The epigenetic landscape of T cell exhaustion. Science 354 (2016), 1165–1169.
61. Shekhar, K., Lapan, S.W., Whitney, I.E., Tran, N.M., Macosko, E.Z., Kowalczyk, M., Adiconis, X., Levin, J.Z., Nemesh, J., Goldman, M., et al. Comprehensive classification of retinal bipolar neurons by single-cell transcriptomics. Cell 166 (2016), 1308–1323.e30.
62. Singer, M., Wang, C., Cong, L., Marjanovic, N.D., Kowalczyk, M.S., Zhang, H., Nyman, J., Sakuishi, K., Kurtulus, S., Gennert, D., et al. A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells. Cell 166 (2016), 1500–1511.e9.
63. Steinke, F.C., Yu, S., Zhou, X., He, B., Yang, W., Zhou, B., Kawamoto, H., Zhu, J., Tan, K., Xue, H.H., TCF-1 and LEF-1 act upstream of Th-POK to promote the CD4(+) T cell fate and interact with Runx3 to silence Cd4 in CD8(+) T cells. Nat. Immunol. 15 (2014), 646–656.
64. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005), 15545–15550.
65. Tirosh, I., Izar, B., Prakadan, S.M., Wadsworth, M.H. 2nd, Treacy, D., Trombetta, J.J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352 (2016), 189–196.
66. Trapnell, C., Pachter, L., Salzberg, S.L., TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25 (2009), 1105–1111.
67. Utzschneider, D.T., Legat, A., Fuertes Marraco, S.A., Carrié L., Luescher, I., Speiser, D.E., Zehn, D., T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat. Immunol. 14 (2013), 603–610.
68. Utzschneider, D.T., Charmoy, M., Chennupati, V., Pousse, L., Ferreira, D.P., Calderon-Copete, S., Danilo, M., Alfei, F., Hofmann, M., Wieland, D., et al. T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity 45 (2016), 415–427.
69. Wang, X., Cairns, M.J., SeqGSEA: a Bioconductor package for gene set enrichment analysis of RNA-Seq data integrating differential expression and splicing. Bioinformatics 30 (2014), 1777–1779.
70. Woo, S.R., Turnis, M.E., Goldberg, M.V., Bankoti, J., Selby, M., Nirschl, C.J., Bettini, M.L., Gravano, D.M., Vogel, P., Liu, C.L., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72 (2012), 917–927.
71. Xu, B., Yuan, L., Gao, Q., Yuan, P., Zhao, P., Yuan, H., Fan, H., Li, T., Qin, P., Han, L., et al. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer. Oncotarget 6 (2015), 20592–20603.
72. Yuan, J., Gnjatic, S., Li, H., Powel, S., Gallardo, H.F., Ritter, E., Ku, G.Y., Jungbluth, A.A., Segal, N.H., Rasalan, T.S., et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. USA 105 (2008), 20410–20415.
73. Zheng, C., Zheng, L., Yoo, J.K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J.Y., Zhang, Q., et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 169 (2017), 1342–1356.e16.
74. Zhou, X., Yu, S., Zhao, D.M., Harty, J.T., Badovinac, V.P., Xue, H.H., Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1. Immunity 33 (2010), 229–240.
75. Zhu, L.J., Gazin, C., Lawson, N.D., Pagès, H., Lin, S.M., Lapointe, D.S., Green, M.R., ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC Bioinformatics, 11, 2010, 237.